Equibles does not estimate personal net worth.
Get an email with a short summary when Arrowhead Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.
Get ARWR alertsDaniel Apel is recorded as CFO at Arrowhead Pharmaceuticals, Inc. (ARWR). The newest filing on record that lists Daniel Apel as CFO at Arrowhead Pharmaceuticals, Inc. (ARWR) is dated January 27, 2026. Arrowhead Pharmaceuticals, Inc. reported in an 8-K filed April 15, 2025 that Daniel Apel was appointed Chief Financial Officer, effective May 13, 2025. Daniel Apel has spoken on 1 earnings call and 1 other investor event across 1 company, most recently for Arrowhead Pharmaceuticals, Inc. on June 10, 2026. Arrowhead Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Arrowhead Pharmaceuticals, Inc. includes Christopher Anzalone (CEO and Board Member), Patrick O'Brien (COO), Patrick O’Brien (COO and General Counsel) and 6 others.
“On April 9, 2025, the Company determined that it would appoint Daniel Apel to serve as Chief Financial Officer of the Company, effective as of May 13, 2024, until the earliest of Mr. Apel's removal, termination, or resignation from such office.”
“Yeah, so just starting with the market opportunity, we've, you know, this is an ultra-rare indication. It's been varying levels of estimates about the population.”
“As we reported today, net loss for the quarter ended March 31, 2026, was $132.7 million, or a loss of 93 cents per share. Based on $142.4 million fully diluted weighted average shares outstanding.”
Start not stated–present
Last confirmed January 27, 2026
Biotechnology · Healthcare
CFO
